Gene expression profiling to monitor therapeutic and adverse effects of antisense therapies for Duchenne muscular dystrophy

Author： ’t Hoen Peter AC   van der Wees Caroline GC   Aartsma-Rus Annemieke   Turk Rolf   Goyenvalle Aurélie   Danos Olivier   Garcia Luis   van Ommen Gert-Jan B   den Dunnen Johan T   van Deutekom Judith CT  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.7, Iss.3, 2006-04, pp. : 281-297

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Gene Replacement Therapies for Duchenne Muscular Dystrophy Using Adeno-Associated Viral Vectors

By  

Current Gene Therapy, Vol. 12, Iss. 3, 2012-06 ,pp. : 139-151

Bentham Science Publishers

Access to resources Recommend Favorite

Personalised Genetic Intervention for Duchenne Muscular Dystrophy: Antisense Oligomers and Exon Skipping

By  

Current Molecular Pharmacology, Vol. 2, Iss. 1, 2009-01 ,pp. : 110-121

Bentham Science Publishers

Access to resources Recommend Favorite

Antisense Oligonucleotide-Mediated Exon Skipping for Duchenne Muscular Dystrophy: Progress and Challenges

By  

Current Gene Therapy, Vol. 12, Iss. 3, 2012-06 ,pp. : 152-160

Bentham Science Publishers

Access to resources Recommend Favorite

Interference with Myostatin/ActRIIB Signaling as a Therapeutic Strategy for Duchenne Muscular Dystrophy

By  

Current Gene Therapy, Vol. 12, Iss. 3, 2012-06 ,pp. : 245-259

Bentham Science Publishers

Access to resources Recommend Favorite

Emerging drugs for Duchenne muscular dystrophy

By Malik Vinod   Rodino-Klapac Louise R.   Mendell Jerry R  

Expert Opinion on Emerging Drugs, Vol. 17, Iss. 2, 2012-06 ,pp. : 261-277

Informa Healthcare

Access to resources Recommend Favorite